GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Healios KK (TSE:4593) » Definitions » LT-Debt-to-Total-Asset

Healios KK (TSE:4593) LT-Debt-to-Total-Asset : 0.12 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Healios KK LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Healios KK's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.12.

Healios KK's long-term debt to total assets ratio declined from Jun. 2023 (0.27) to Jun. 2024 (0.12). It may suggest that Healios KK is progressively becoming less dependent on debt to grow their business.


Healios KK LT-Debt-to-Total-Asset Historical Data

The historical data trend for Healios KK's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healios KK LT-Debt-to-Total-Asset Chart

Healios KK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.30 0.27 0.03 0.18

Healios KK Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 0.03 0.12 0.18

Healios KK LT-Debt-to-Total-Asset Calculation

Healios KK's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=2546/14191
=0.18

Healios KK's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=2049/17811
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healios KK  (TSE:4593) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Healios KK LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Healios KK's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Healios KK Business Description

Traded in Other Exchanges
Address
World Trade Center Bldg. 15th Floor, 2-4-1 Hamamatsucho, Minato-ku, Tokyo, JPN, 105-6115
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy.

Healios KK Headlines

No Headlines